The 2024 AAA Annual Conference is in Atlanta, Georgia April 17–20 at the Georgia World Congress Center. This four-day event has audiology research and clinical leaders presenting on a wide range of topics. It’s possible to earn up to 3.2 CEUs during the conference while you network and catch up with friends and colleagues. There’s even a special event where you can “Paws and Relax” and meet a new puppy friend!
For current ABA certificate holders, AAA 2024 provides an opportunity to obtain the specialized CEUs required to maintain your certification. As a reminder, here are the CEU requirements for the ABA certificants:
ABAC: At each annual renewal, certificants must meet the following recertification requirements:
- Completion of 20 hours of continuing education, with five of these hours at the Tier 1 level and one hour in professional ethics.
PASC: At the end of each three-year certification cycle, certificants must meet the following recertification requirements:
- Completion of 60 hours of continuing education, with 15 of these hours at the Tier 1 level and three hours in professional ethics.
- 30 of the total 60 continuing education hours must pertain to pediatric audiology.
CISC: At the end of each three-year certification cycle, certificants must meet the following recertification requirements:
- Completion of 60 hours of continuing education, with 15 of these hours at the Tier 1 level and three hours in professional ethics.
- 30 of the total 60 hours of continuing education must pertain to cochlear implants.
Recent Posts
Audiology CPT® Codes Enter Routine AMA RUC Review Process
Over the next several months, a significant number of CPT® codes used to report audiology function tests will undergo review through the AMA/Specialty Society Relative…
Academy Advocacy on Capitol Hill for Student Loan Reform and EHDI Support
Last week, Joanne Zurcher, MPP, and Academy member Melissa Heche, AuD, traveled to Capitol Hill to advocate for two important Academy priorities: protecting access to…
A New Era in Hearing Care: FDA Approves OTOF Gene Therapy
In the United States, mutations in the OTOF-gene (otoferlin gene) account for between one percent and eight percent of non-syndromic congenital hearing loss (Ford et…



